Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same
AssigneeAstraZeneca AB
InventorAnna Maria LANGKILDE
Life of this patent
Estimating the term…
Abstract
Methods for treating and/or preventing HFpEF and/or at least one disease, disorder, and/or condition associated therewith in patients by the use of dapagliflozin and compositions comprising the same are disclosed.
Claims21
1-86. (canceled)
A method for reducing the risk of cardiovascular (CV) death, hospitalization for heart failure (HF), and urgent HF visits in a non-diabetic patient with HF with preserved ejection fraction (HFpEF), the method comprising administering to a non-diabetic patient a therapeutically effective amount of at least one compound chosen from compounds of Formula (I)
- and prodrugs thereof.
A method for reducing the risk of cardiovascular (CV) death, hospitalization for heart failure (HF), and urgent HF visits in a non-diabetic patient with HF with preserved ejection fraction (HFpEF), the method comprising administering to a non-diabetic patient 10 mg of dapagliflozin
- once daily.
Dependencies are inferred from the claim text.